Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Corren

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 1, 2020
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitisWilliam W Busse, Jorge F Maspero, Yufang Lu, et al.
The New England Journal of Medicine|May 22, 2018
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaMario Castro, Jonathan Corren, Ian D Pavord, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 28, 2019
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic RhinosinusitisJorge F Maspero, Constance H Katelaris, William W Busse, et al.
Chest|February 1, 2026
Sex does not modify prediction of asthma attacks by clinical risk factors and Type-2 biomarkersSebastian Riemann, Fleur L Meulmeester, Samuel Mailhot-Larouche, et al.
The Lancet. Respiratory Medicine|April 11, 2025
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trialsFleur L Meulmeester, Samuel Mailhot-Larouche, Carlos Celis-Preciado, et al.
Allergy|June 3, 2020
EAACI Biologicals Guidelines-Recommendations for severe asthmaIoana Agache, Cezmi A Akdis, Mubeccel Akdis, et al.
Allergy|February 9, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Jessica Beltran, Cezmi Akdis, et al.
Allergy|March 11, 2020
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthmaIoana Agache, Yang Song, Claudio Rocha, et al.
Allergy|February 18, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Claudio Rocha, Jessica Beltran, et al.
The World Allergy Organization Journal|May 20, 2020
COVID-19, asthma, and biological therapies: What we need to knowMário Morais-Almeida, Rita Aguiar, Bryan Martin, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 1, 2020
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitisWilliam W Busse, Jorge F Maspero, Yufang Lu, et al.
The New England Journal of Medicine|May 22, 2018
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaMario Castro, Jonathan Corren, Ian D Pavord, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 28, 2019
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic RhinosinusitisJorge F Maspero, Constance H Katelaris, William W Busse, et al.
Chest|February 1, 2026
Sex does not modify prediction of asthma attacks by clinical risk factors and Type-2 biomarkersSebastian Riemann, Fleur L Meulmeester, Samuel Mailhot-Larouche, et al.
The Lancet. Respiratory Medicine|April 11, 2025
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trialsFleur L Meulmeester, Samuel Mailhot-Larouche, Carlos Celis-Preciado, et al.
Allergy|June 3, 2020
EAACI Biologicals Guidelines-Recommendations for severe asthmaIoana Agache, Cezmi A Akdis, Mubeccel Akdis, et al.
Allergy|February 9, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Jessica Beltran, Cezmi Akdis, et al.
Allergy|March 11, 2020
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthmaIoana Agache, Yang Song, Claudio Rocha, et al.
Allergy|February 18, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Claudio Rocha, Jessica Beltran, et al.
The World Allergy Organization Journal|May 20, 2020
COVID-19, asthma, and biological therapies: What we need to knowMário Morais-Almeida, Rita Aguiar, Bryan Martin, et al.
Pageof 15